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ABSTRACT:
Human Papillomavirus (HPV) induced cancers continue to affect millions of
women worldwide, with the five year survival rate hovering just under 60% in some
demographics.

Therefore there is an unmet need to develop effective, yet, easily

administered therapies to treat established HPV genital lesions. Even though immune
checkpoint therapy (ICT) is a promising treatment option in some HPV+ cancers, the
high cost and associated toxicities are still major concerns for their widespread
application. HPV cancers are textbook candidates for therapeutic vaccination
intervention because they’re driven by the expression of viral oncoproteins E6 and E7,
which serve as ideal tumor specific antigen targets. An effective therapeutic vaccine
should be able to overcome tumor mechanisms of immune-evasion and immunesuppression, while inducing a robust anti-tumor mediated response. In this dissertation
I investigated a novel therapeutic HPV peptide vaccination strategy; by incorporating two
diverse acting adjuvants for induction of strong cytotoxic effector immunity, and utilizing
the intranasal mucosal route of immunization to ensure efficient trafficking to the genital
v
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mucosal tumors.

Overall, I hypothesized that intranasal HPV peptide vaccination

employing the combination of TLR9 and NKT cell ligands, (CpG-ODN and α-GalCer,
respectively) will induce potent systemic and mucosal antigen-specific CD8 T cell
response, specifically at the female reproductive tract (FRT) to eliminate HPV genital
tumors.
Utilizing an orthotopic vaginal tumor model in mice, I obtained evidence
demonstrating the efficacy of the therapeutic HPV peptide vaccine containing α-GalCer
and CpG-ODN (TVAC), in terms of inducing sustained and efficient tumor regression in
nearly 85% of treated mice. The therapeutic efficacy correlated with significant CD8 T
cell responses and increased ratios of cytotoxic effector to immune suppressive
populations (regulatory T cells and myeloid derived suppressor cells) in the tumor
microenvironment. Treatment with TVAC was also effective against tumors implanted in
the flank, representing a systemic HPV tumor model. These results support the feasibility
and benefits of utilizing intranasally delivered therapeutic vaccines formulated with
combinations of diverse acting adjuvants, such as the TVAC tested in this investigation,
as a potential strategy for clinical development to treat established genital HPV tumors.
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CHAPTER 1. INTRODUCTION
HPV induced cervical cancers are the second leading cause of death in women
worldwide. Despite the availability of preventative vaccines, millions of people who have
already been exposed to the virus, or are ineligible/unable to receive the vaccine are still
at risk of developing cancer and requiring treatment. Therefore there is an unmet need
for the development of an easily administered therapy for the treatment of HPV induced
cancers. HPV driven cancers constitutively express viral gene products (e.g. E6 and E7)
necessary to induce oncogenic transformation, thereby making them ideal targets for
treatment using a therapeutic vaccine.
Therapeutic vaccines are used to boost or modulate the immune response to treat
existing ailments such as viral infections or cancers [1]; in contrast to prophylactic
vaccines which offer protection against initial infection [2].

Similar to prophylactic

vaccines, however, therapeutic vaccines are often made up of two components to induce
an effective immune response; the first is an immunogen such as a bacterial toxin or
pathogen-encoded antigen, foreign to the host, the second component is an adjuvant, or
substance which enhances the body's immune response to the co-administered
immunogen/antigen [3].

Different classes of adjuvants capable of modulating and

inducing immune responses in different sets of immune cells are available, and therefore
the selection of safe yet effective adjuvants is a key aspect for the development of a
successful vaccine. In addition, therapeutic vaccines must be effective at inducing the
proper immune response at the site of infection or cancer. This dissertation investigates
the potential of two diverse-acting adjuvants, α-GalCer and CpG-ODN, as components
1
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of a therapeutic peptide vaccine for the treatment of HPV genital tumors.

I also

investigated different routes of vaccine delivery for determining the most effective
regimen for therapeutic efficacy against HPV genital cancer.
In the following chapters, I will first review the role of HPV and other viruses in the
development of cancer, how HPV, in particular, evades immune recognition permitting
cancer progression, and the overall burden HPV induced cancers have globally. I will
also discuss the various therapeutic approaches that have been developed to treat HPV
induced cancers, and how the compartmentalization of the mucosal immune system can
play a role in therapeutic efficacy. Lastly, I will discuss the main questions and rationale
of my research.
1.1 HPV and Cancer
Cancer is defined by the National Institute of Health (NIH) as a group of diseases
in which abnormal cells divide without control with the potential to invade nearby tissues.
They are often categorized by the type of tissue the cancer originates from, and the
primary site of the disease. Carcinomas and sarcomas are cancers originating in the
epithelial layer and supportive/connective tissues of the body, respectively, while
leukemia and lymphomas are cancers of the bone marrow and glands or lymph nodes.
A fifth category of cancer classification includes a mixed type of cancer, in which the
growths are found in multiple categories.
It is difficult to identify the exact cause of cancer, however, in 1971 Alfred G.
Knudson formulated the two-hit hypothesis which describes the notion that two “hits” or
defects in the DNA-encoding tumor suppressor genes were required to induce the
2
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hereditary cancer, retinoblastoma [4]. Although we now know that there are more factors
at play for the development of cancer, this theory indirectly led to the identification of
major oncogenes, or genes that, under certain situations, can transform a healthy cell
into a tumor cell. The process of cancer transformation not only depends on the mutation
of tumor suppressor genes, but requires a combination of characteristics termed the
Hallmarks of Cancer which were describe by Hanahan and Weinberg [5].

These

hallmarks include self-sufficient growth signals, insensitivity to anti-growth signals,
evading programmed cell death, limitless replicative potential, sustained angiogenesis,
tissue invasion and metastasis, deregulated metabolism, and evading the immune
system.
Several external or environmental factors have been found to directly increase the
likelihood of cancer. These include smoking, tobacco use, poor diet, lack of physical
activity, exposure to radiation, and infections [6, 7]. In fact, approximately 15% of all
cancers are caused by viral infections [8, 9]. There are currently seven recognized
viruses which are known to cause cancer, termed oncogenic viruses. These viruses and
their associated cancers are listed in Table 1 [9]. Oncogenic viruses have the capacity
to prompt unregulated cell replication and uncontrolled growth. In certain cases, an
oncogenic virus is able to embed their genetic material into the host genome, allowing
for the cell’s transformation into cancer. Although HIV does not directly cause cancer
and is not listed in this table, it is important to note that, because it causes
immunodeficiency, it increases the risk of cancer by reducing the body’s ability to fight
off or control other oncogenic viruses or infections [10-12].
3
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Table 1 Association of viruses and cancer. The seven known oncogenic viruses
alongside the type (s) of cancer(s) they are associated with [9].
ONCOGENIC VIRUS

CANCER TYPE

HUMAN PAPILLOMA VIRUS (HPV)

Cervical, Penile, vulvar, vaginal, head and neck
squamous cell carcinoma (HNSCC)
Stomach cancers, nasopharyngeal cancers,
and Burkitt or Hodgkin lymphomas.
Kaposi Sarcoma,

EPSTEIN-BARR VIRUS (EBV)
HUMAN HERPES VIRUS 8 (HHV-8)
HUMAN T LYMPHOTROPIC VIRUS
TYPE I (HTLV-1)
HEPATITIS B VIRUS (HBV)
HEPATITIS C VIRUS (HCV)
MERKEL CELL POLYOMA VIRUS
(MCPYV)

Non-hodgkin lymphoma (adult T cell
leukemia/lymphoma), and lymphocytic
leukemia
Liver Cancer
Liver Cancer, also increases the risk of nonHodgkin lymphoma and head and neck
cancers.
Merkel cell carcinoma (MCC)

Currently, there are only three FDA approved vaccines for protection against
these oncogenic viruses. They include vaccines for the prevention of HBV, HPV, and
EBV [13]. Despite their availability, however, vaccination rates for each of these viruses
vary greatly depending on region and among virus [7].
This dissertation will focus on human papillomavirus (HPV) as it is the most
common sexually transmitted disease, is responsible for nearly 100% of cervical cancers
worldwide, 70% of vaginal and vulvar cancers, 60% of penile cancers, 90% of anal
cancers, and approximately 60-70% of newly diagnosed oropharynx cancers [14]. In the
next section, the virology and oncogenic mechanisms of HPV will be described, followed
by the virus’ global impact.
4
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1.1.1 Virology of HPV
HPV is an 8kb double-stranded DNA virus containing 8 protein-coding genes.
There are currently over 200 identified strains of HPV, each having less than 10%
homology with the rest [15, 16]. The HPV DNA can be categorized into three sections
based on the genes it encodes or the function it provides: the noncoding upstream
regulatory region (URR), the early protein coding region which of the virus encodes the
replication machinery (E1, E2, E4, E5, E6, and E7), and the late protein encoding region
which encodes the capsid proteins (L1 and L2) [17]. The virus’s replication cycle is
dependent on the differentiation of the epithelial cells it infects. Initial infection begins at
the basal layer of the epithelial layer where the virus gains access to these cells through
naturally occurring micro-lesions in the epithelia, and begins early gene expression. The
expression of E6 and E7 genes helps drive the epithelial cells into the S-phase, creating
an ideal viral replication environment during host cell proliferation. As new cells develop
in the basal epithelia, infected cells move into the upper epithelial layers, where the virus
begins the production of the late genes required for capsid assembly and eventually
progeny release [18]. HPV is not a lytic virus, meaning that it does not need to kill, or
lyse the cell it infects to release its progeny. It is released when the epithelial cell it
infects, reaches the top of the epithelium and is shed naturally, avoiding virus-induced
necrosis and inflammation.

This is one of the many ways HPV is able to remain

undetected in its host and will be discussed in further detail in the next section [19].
There are 14 identified oncogenic or “high-risk” strains of HPV. HPV16 and
HPV18 are the most common “high-risk” strains and are responsible for approximately
5
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70% of cervical cases around the world [20, 21]. Two of the most common “low-risk
strains”, which induce genital warts, but do not lead to cancer, are HPV6 and HPV11,
accounting for over 90% of genital warts cases [22]. It is predicted that over 80% of the
population has been or will become infected with at least one strain of HPV in their
lifetime, however, the majority of these cases are asymptomatic and cleared naturally by
the immune system [18]. When a host becomes infected with what is considered a “highrisk” HPV strain, and is unable to clear the virus (chronic infection), changes to the virus’s
genome can lead to integration of the viral genome into the host cell DNA [23, 24].
Continuous and overexpression of HPV E6 and E7 are the main drivers of HPV induced
cancers; as previously mentioned, these proteins are capable of driving the host cell into
uncontrolled proliferation. E6 induces the degradation of p53, a tumor-suppressing
molecule, while E7 binds to and inhibits retinoblastoma (Rb) from binding with E2F, a
protein, which when is unbound, leads to cell cycle activation and proliferation (Fig. 1)
[25]. With both of these proteins overexpressed in the host cell, the healthy cells
transform into cancerous ones.

6
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Figure 1. HPV E6 and E7 mechanisms of oncogenic transformation. HPV16 E6 and
E7 are the main drivers of oncogenic transformation. E6 is known to bind and degrade
p53, a major tumor suppressor gene within the host cell, while E7 competitively inhibits
the binding of pRB and E2F. By doing so, the unbound E2F protein is able to induce cell
cycle activation and proliferation. Figure created with BioRender.com

7
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1.1.2. Mechanisms of HPV immune evasion
The immune system is a complex network of cells, tissues, and organs that aids
the body to fight off infections. It is comprised of the innate and adaptive immune
systems that work together to control and eliminate pathogens, such as HPV, and can
also prevent re-infection. The innate immune system is a rapid, non-specific defense
mechanism that includes physical barriers such as the skin, defense mechanisms such
as secretions and mucus, and innate immune cells. Innate immune cells, including but
not limited to natural killer (NK) cells, natural killer T (NKT) cells, macrophages and
dendritic cells (DCs), are capable of recognizing microbial substances through the use
of pattern recognition receptors (PRRs). These PRRs, in response to an invading
pathogen, activate downstream signaling pathways to promote a protective inflammatory
immune response through the release of cytokines such as IFNγ, TNF-α, and
granulocyte macrophage colony-stimulating factor (GM-CSF).
The adaptive immune system is a highly regulated and antigen specific part of the
immune system that includes B cells and T cells. While CD4 T cells recognize peptides
presented on MHC class II and are referred to as “helper T cells”, CD8 T cells recognize
peptides on MHC class I molecules and are often referred to as cytotoxic T lymphocytes
(CTLs), as they are able to directly kill infected or cancerous cells. CD4 helper T cells
aid in tailoring the immune response to the type of pathogen encountered. They release
a multitude of cytokines to either prime B cells for antibody release and pathogen
neutralization or activate dendritic cells, a type of antigen presenting cell (APC) to
educate and activate CD8 T cells for cell-mediated killing.
8
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Dendritic cells are known as the main bridge between the innate and adaptive
immune systems since they are able to take up, process, and present antigens to the
adaptive immune cells, inducing antigen-specific immunity.

Dendritic cells require

stimulatory signals in order to present co-stimulatory molecules required for CD8 T cell
activation. These signals can be from inflammatory cytokine responses, or CD4 T cell
responses [26].
HPV can avoid both innate and adaptive immunity in approximately 10% of
infected individuals through several specific mechanisms briefly described here. Further
details can be found in the following reviews [27, 28].
During the initial infection stage, the virus is able to enter the basal epithelial cells
through naturally occurring micro lesions, and by maintaining low copy numbers, it avoids
immune detection [27]. As the infected basal cells grow and enter the differentiation
phase of the epithelium, the virus significantly upregulates viral gene expression and
DNA replication, wrapping up its replication process as the infected cell reaches its
terminal differentiation phase at the top of the epithelium, naturally dying and shedding
the HPV viral progeny as it is released. By circumventing virus-induced cell death and
the associated inflammation, HPV is able to avoid triggering the influx of APCs to the
infection site [27]. Additionally, because HPV is localized to the epithelium, it avoids the
blood stream and lymphatic system where it can be detected by the host. Studies also
indicate that high-risk HPV strains downregulate interferon gene responses necessary
for antiviral and innate immune response, although this is still not thoroughly understood
[29].
9
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As previously mentioned, approximately 10% of HPV infections with high risk
strains that remain undetected experience viral mutations and result in oncogenic
transformation [30]. Failure to induce cellular immunity against infected cells, and viral
genome integration or deregulation are vital steps that cause HPV infections to lead to
cancer. As the cancer progresses, regulatory T cells (Tregs) and Myeloid Derived
Suppressor Cells (MDSCs) significantly increase within the affected site, abrogating CD8
T cell responses, and further aiding tumor growth [31].
1.1.3. Global burden of HPV and promise of a vaccine
HPV driven cancers make up four percent of total cancer diagnosis every year,
amounting to a total of almost 700,000 cases, with the majority of patients being women
diagnosed with cervical cancer [32]. Frequencies and impact of HPV induced cancers
vary greatly between countries of different economic statuses. While they make up less
than three percent of cancer diagnoses in Australia and the United States, they account
for 26% in sub-Saharan African countries [33]. Even within the United States, economic
and racial disparities depict a correlation with those who are diagnosed with HPV cervical
cancer [34]. Studies indicate that a lack of regular screenings, access to affordable
medical care, and vaccination rates contribute to these disparities in the US and around
the world [33, 35].
The prophylactic vaccine Gardacil9 is currently offered and approved for the
prevention of HPV infection, significantly reducing the risk of HPV-induced cancers by
up to 90% [36, 37]. This vaccine and its predecessors were originally targeted at
10
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protecting women against cervical cancer, but because HPV infects and is transmitted
by men and women, it is now recommended that both males and females of adolescent
age be vaccinated against HPV in order to reduce transmission and protect against
cervical, penile, anal, vaginal, vulvar, and oral cancers [36, 38-40]. The Gardacil9
vaccine is composed of virus-like particles (VLPs) corresponding to the major capsid
proteins on the surface of the virus, L1, which are immunogenic on their own. It induces
immunity and provides protection against the seven most common oncogenic HPV
strains, HPV16, 18, 31, 33, 45, 52 and 58, plus the two strains responsible for genital
warts, HPV 6 and 11 [41].

Admixed with aluminum salts, amorphous aluminum

hydroxyphosphate sulfate (AAHS), studies indicate that even just a single dose is
sufficient to significantly reduce the risk of cancer [42, 43].
Despite the vaccine’s availability, global HPV infections remain high. Originally
released in 2006, delays in vaccine uptake and availability rendered millions of adults
ineligible for the vaccine because it is not recommended for those with preexisting
infections.
The current standard of care for patients diagnosed with cervical cancer varies
depending on the severity and spread of the disease but typically involves the surgical
removal of the affected area plus a combination of either chemotherapy or radiation
therapy. This approach often comes with toxic side effects, lowering the quality of life for
affected individuals [44-46]. In addition, the overall five year survival rate of women
treated for cervical cancer is still less than 60% in some demographics [21]. Therefore,
there is an unmet need for the development of more effective, yet low-cost and easily
11
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administered treatment options for HPV induced cancers without the use of
chemotherapy and radiation therapy.
1.1.2. Therapeutic alternatives for HPV induced cancers
Over the years, various approaches have been taken to treat HPV-induced
cancers, with the overall goal of shifting away from chemotherapy and radiation therapy.
In the following section I will briefly describe some of these methods including checkpoint
inhibitors, cell based vaccines and therapeutic vaccines. It is important to reiterate that
the currently available prophylactic vaccine described in the preceding section is not an
effective treatment for existing HPV infections, as it only protects against initial infection.
As previously mentioned, the prophylactic vaccine induces immunity against the surface
proteins of the virus, allowing it to neutralize the virus prior to entering and infecting the
host cell [21, 36]. These late genes encoding the surface proteins, along with a portion
of the early genes are often lost during viral DNA integration into the host genome [23,
24]. Therefore, the majority of the following therapeutic approaches focus on inducing
or enhancing cellular immunity against HPV proteins E6 and E7 as they are the primary
drivers of cell transformation and cancer. In addition, these proteins are constitutively
expressed in HPV induced cancers, and targeting these virus-specific proteins avoids
off-target effects. Recent studies have also identified the constitutive expression of the
E5 protein in a large percentage of cancers, signifying that it could serve as a third
antigenic target of interest [47].
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One promising method of enhancing cellular immunity for the treatment of HPV
induced cancers is the use of checkpoint inhibitors.

Studies indicate that patients

progressing from early stage HPV disease to higher grades express increased levels of
PD-1 and PDL-1 on the infiltrating T cells and DCs, significantly dampening the antitumor immune response [48].

Utilization of checkpoint inhibitors to block these

dampening functions of PD-1 and PDL-1, allows the infiltrating CD8 T cells to continue
killing infected cells [49]. Many ongoing clinical trials are testing the potential of these
and other checkpoint inhibitors such as CTLA-4, alone and in combination with traditional
HPV therapies and are listed in detail in the following review [50].
In addition, cell-based therapies for treatment of advanced and non-responding
cancers have also been receiving growing interest. Cell therapies include adoptive T cell
transfer, dendritic-cell vaccines, CAR-T cell therapies, and treatment with engineered
TCR T cells. These methods all involve the isolation of cells of interest, such as dendritic
cells or T cells from a patient, performing ex-vivo manipulations to increase therapeutic
potential, and infusing these cells back into the same patient.
For example, DCs pulsed with recombinant HPV proteins, stimulated ex vivo and
transferred into cervical cancer patients increase antigen specific immunity in the blood
[51-53]. Although this method showed efficacy for inducing CTL response systemically,
a clinical response was not observed [52].
A more direct approach involves the isolation of tumor infiltrating lymphocytes
(TILs) from cervical cancer patients, and clonally expanding those specific to the patient’s
tumor through the use of cytokines and HPV peptides, or genetically modifying them for
13
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antigen specificity. This method is a highly personalized form of medical treatment and
has shown great clinical response in patients [54, 55].
While these therapies are currently used in clinics and have shown promising
results, they are often very time consuming and costly.

In the following chapter, I will

describe the multiple types of therapeutic vaccines that have been developed and
proposed for HPV induced cancers, while including few examples that have been tested
in clinical trials.
1.2. Therapeutic Vaccines
Therapeutic vaccines are designed to boost or modulate immune response to
treat existing ailments such as viral infections or cancers, in contrast to prophylactic
vaccines which offer protection against initial infection [2]. Several types of therapeutic
vaccines have been developed for the treatment of HPV induced cancers.

These

vaccines, as previously mentioned are aimed at inducing cellular immunity against the
HPV proteins E6 and E7 as they are the main drivers of oncogenic transformation. One
major distinction between these therapeutic approaches is in the antigen formulation
used. These include the use of viral vectors, proteins, peptides, and DNA for the delivery
of antigens. The following section will describe each of these approaches along with
some examples and benefits and disadvantages of each.
1.2.1. Live vector based vaccines
Viral and bacterial vector based vaccines utilize recombinant vectors encoding
HPV target antigens to infect host cells with the main goal to get recognized by APCs.
14
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Once within the cell, viral and bacterial vectors are able to produce the target antigens
or peptides, promoting antigen presentation. In order to increase immunogenicity of this
approach and ensure the infected cell is recognized by the immune system, the vectors
typically also encode stimulatory factors such as IL-2 [56, 57] or pathogen associated
molecular patterns (PAMPs) [58].

Upon successful infection and translation of the

encoded antigens, the vector activates downstream sequence of events, inducing an
inflammatory response against the target antigen.
One approach, utilizing live attenuated Listeria monocytogenes encoding HPV16
E7 protein linked to listeriolysin O (TG4001) showed promising pre-clinical results,
however, clinical safety and efficacy are still undergoing in cervical cancer patients with
recurring disease [56]. Another group utilized a modified vaccinia virus Ankara vector
for the production of E6 or E7 proteins of HPV along with IL-2, which has shown success
in inducing antigen specific CD8 T cell responses in patients [56]. Additionally, vaccinia
vectors, adenovirus vectors, and semliki forest virus vectors have also been used for the
development of therapeutic HPV vaccine candidates [56, 59, 60].
Although effective measures are taken to ensure safety profile of these vaccines,
utilizing live viral vectors continues to pose safety concerns as the risk of DNA mutation,
integration and pathogenic potential in immunocompromised patients is a genuine risk
.[61] In addition, because live attenuated viruses are also slightly immunogenic, there is
the possibility of the patient’s immune system recognizing the viral antigen and inducing
immunity against the treatment itself [62].
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1.2.2 Protein and peptide based vaccines
Protein and peptide based vaccines have long been proposed for the treatment
of HPV induced cancers [63]. This approach consist of delivering recombinant proteins
or peptides from HPV to be taken up, processed and presented by DCs, inducing an
antigen specific CD8 T cell response. Interests remain high in these categories, in
particular peptide based vaccines, due to the low cost of production, long term stability,
and high safety profiles. This approach does not carry concerns associated with the use
of vector or DNA based vaccines, however, they do require the use of adjuvants due to
low immunogenicity. Co-administration with adjuvants such as chemokines, toll-like
receptor ligands, or lipids have shown to increase immunity against these peptide,
resulting in enhanced CD8 T cell responses [63]. One hurdle of utilizing peptides for
immune induction is the specificity of different epitopes to MHC types. Not all peptides
have high affinity or compatibility to certain MHC types, therefore depending on the
peptides of choice, these vaccines can be specific to different HLA haplotypes. One
method to circumvent this is the use of long overlapping peptides covering the entire
protein sequence. This ensures complete coverage of the proteins of choice while
avoiding oncogenic risks of delivering the entire protein. Additionally, whole protein
administration typically results in longer peptide presentation on MHC class II molecules,
shifting the immune response towards a CD4 T helper immune response [64].

A

Synthetic Long Peptide (SLP) vaccine which utilizes HPV16 E6 and E7 peptides coadministered subcutaneously with Montanide ISA-51 adjuvant is currently in clinical trials
for HPV driven gynecological and oral cancers [65].
16

TITLE PAGE
1.2.3. DNA vaccines
DNA and RNA based vaccines are another emerging field of interest as they utilize
genetic material with the capability to produce full-length protein or peptides, allowing for
natural processing and presentation by APCs[66]. Precautions and modifications to the
full-length protein approach must be taken, however, to prevent the risk of causing
cellular transformation [67]. DNA and RNA constructs are economically feasible for large
scale production, but DNA holds better stability than RNA [68]. DNA vaccines are poorly
immunogenic and require the use of adjvuants, similar to protein and peptide vaccines
[68].
One example of a DNA vaccine encoding a full-length protein construct shuffled
the gene sequence of HPV E6 and E7 in a way that disabled the oncogenic potential of
translated proteins, but still allowed for processing of the proteins and proper epitope
presentation for efficient E6 and E7 induced immunity [69]. Although this approach has
proven to induce robust immunity even in pre-clinical models, clinical outcome was not
as robust as anticipated [70].
1.2.4. Genome editing
The latest approach and last one that will be covered in this chapter is the use of
genome editing tools to reduce the expression of the driving oncogenes. Pre-clinical
models in vitro and in vivo have shown the power of using the CRISPR/Cas9 genome
editing system in order to cleave the HPV16/18 E7 oncogene embedded in the host DNA,
allowing for cell-induced apoptosis and reduction of tumor growth [71, 72].
17
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Because primary HPV lesions are found at mucosal sites, it’s important but often
overlooked, for a therapeutic vaccine to induce an immune response at these locations.
Many pre-clinical studies are tested against subcutaneously implanted HPV gene
expressing tumor models and show promising results, however, lack investigations
focusing on immune induction in the genital mucosa [73-76].

A more thorough

understanding of the mucosal immune system can benefit the advancement of
therapeutic HPV vaccines.
1.3. Mucosal immunology and Vaccines
The majority of HPV induced cancers are localized to the genital mucosa, with an
increasing percentage occurring in the oral mucosa. Therefore, therapeutic efforts must
ensure not only a robust immune response, but also proficient cellular immunity at the
genital tract, or female reproductive tract (FRT). As previously mentioned, the oncogenic
proteins of HPV E6 and E7 are the primary targets of therapeutic vaccine approaches.
Although several strategies have proven effective for the induction of a cellular immune
response against these antigens, clinical outcome has not reflected pre-clinical
expectations. Increasing tumor infiltration is a current challenge facing many of the
previously described vaccination approaches. In the following section I will describe the
compartmentalization of the mucosal immune system and prospective benefits of
mucosal vaccinations.
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1.3.1. Compartmentalization of the Mucosal Immune system
The mucosal immune system is a highly compartmentalized portion of the overall
immune system. It functions independently from the systemic immune system and is
responsible for discriminating harmful pathogen encountered from non-pathogenic or
commensal bacteria at the mucosal membranes throughout the body [77, 78]. It consists
of the gastrointestinal, genital, and respiratory tracts which are constantly being exposed
to foreign microbes through the functions of gas exchange, nutrient absorption and
reproduction, therefore the overall nature of the mucosal immune system is highly
tolerogenic, avoiding unnecessary inflammatory immune responses to commensal
bacteria and nutrients. Despite the tolerogenic nature of the mucosal immune system,
the mucosal epithelial layers are lined with what is an equivalent to the systemic lymph
nodes specific for mucosal immunity [78]. The Mucosal-associated lymphoid tissues
(MALT) are situated adjacent to mucosal tissues and make up a complex network of
lymphoid structures similar to lymph nodes of their corresponding mucosal tissue [79].
They are classified into several compartments including the Gut-Associated Lymphoid
Tissues (GALT), the nasopharynx-associated lymphoid tissues (NALT), the conjunctivaassociated lymphoid tissue (CALT), the vaginal associated lymphoid tissue (VALT), and
the bronchus-associated lymphoid tissues (BALT). Presence of these structures can
vary between species, however, their functions are similar, and are the sites where
antigen-specific immune responses are initiated. Each of these components make up
portions of the common mucosal immune system, which is able to induce immune
activation at one mucosal site, disseminate and arise at a distal site [80]. Many studies
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have found that the route for mucosal immunization can heavily influence the resulting
immune response [81-83]. Oral, vaginal, rectal, and nasal vaccinations have all been
investigated and will be briefly discussed below.
Currently, there are only six mucosal vaccines approved for human use targeting
the prevention of the following infections; cholera, rotavirus, salmonella, and influenza.
All are administered orally except for Flumist®, which protects against influenza and is
the only intranasal vaccine currently available for human use [84]. The once orally
administered polio vaccine that aided in the eradication of the disease in the United
States is no longer commercially available after a handful of cases reporting the live
attenuated virus reverting its virulence and causing vaccine-associated paralytic
poliomyelitis [85]. Protection against polio is now achieved through the intramuscular
immunization using an inactivated polio vaccine (IPV), eliminating the risk of utilizing a
live virus for immunization.
The ease and non-invasive nature of oral and nasal vaccine administration make
these routes attractive for mass-scale vaccination, however, route selection depends on
intended immune outcome.

While oral immunizations have the capacity to induce

immunity at the oral tissues and gastrointestinal tract, nasal immunizations have been
shown to induce immunity in the nasal tissues, respiratory tract, and interestingly, studies
have demonstrated immune response at the female reproductive tract (FRT) after
intranasal vaccinations [86]. Vaginal and rectal vaccinations induce less disseminated
responses but are capable of inducing immunity at the genital tissues and gut,
respectively.

While most mucosal vaccinations induce both systemic and mucosal
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immunity, the reverse is not always true. Intraperitoneal vaccinations repeatedly failed
to induce any mucosal immune response [87-89]. These characteristics are important
to note when developing drugs to combat infections like HPV which reside primarily in
the mucosal microenvironment.
One of the benefits of utilizing the mucosal route of immunization is mucosal
imprinting. Mucosal imprinting refers to the ability of mucosally derived DCs to induce
upregulation of mucosal-specific homing receptors on activated T cells. Studies show
that mucosal DCs derived from the lung or gut, are able to induce upregulation of related
integrin and homing receptors such as CD49a and α4β7, respectively [90, 91], therefore
mitigating the localization of the resulting immune responses. Imprinting mechanisms
been investigated for various immunization routes, but the majority of detailed studies
have been on GALT and gut-homing mechanisms. It’s been shown that GALT DCs,
specifically CD103+ DCs from the lamina propria are the only cells able to generate guttropic CD8+ effector cells in vitro. This indicates that the priming APC is the primary factor
responsible for mucosal imprinting, and not so much the location of the priming [91].
1.3.3. Mucosal Adjuvants
Similar to systemically delivered vaccines such as intramuscular or subcutaneous
vaccines, immune response is greatly enhanced with the use of adjuvants. Mucosal
adjuvants have historically been non-toxic derivatives of bacterial toxins such as cholera
toxin (CT), bacterial DNA, virus like particles, and cytokines/chemokines. Although all
are able to induce robust immune responses, not all are safe for use in humans. A
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commonly used derivative of heat-labile enterotoxin (LT), for example proved to be toxic
in humans when used in clinical studies [92]. In another instance, administration of CT
via the intranasal route showed evidence of it trafficking into the brain, therefore also
deemed unsafe [93].
Bacterial DNA such as CpG-ODN, has however shown successes in clinical trials
when delivered intranasally and orally with no apparent toxicities [94]. CpG-ODN is a
TLR9 agonist, and is capable of inducing APC activation, increasing CD80/86 levels, and
skewing immunity towards a CD8 mediated response [94, 95]. Monophosphoryl lipid A
(MPL) is another TLR agonist that binds to TLR4 on APCs and has recently been
approved by the FDA for intramuscular immunization of the prophylactic vaccine against
HPV infections-Cervarix [96]. Several pre-clinical trials which contain MPL have resulted
in robust immune responses when delivered intranasally [97]. A more thorough review
of mucosal adjuvants and their use in clinical trials can be found here [98, 99]
1.3.4. α-GalCer as a mucosal adjuvant
α-Galactosylceramide (ɑ-GalCer), a NKT cell ligand which was originally derived
from a marine sponge, has shown great use as a potent NKT cell agonist. It is taken up
by APCs, and presented on CD1d molecules, inducing the rapid activation of NKT cells.
This activation results in a rapid and robust release of pro-inflammatory cytokines
including IFN-ɣ, IL-2, and IL-4, which in turn causes activation of NK cells, CD8 cells, B
cells, and DCs [100, 101]. Although α-GalCer has been deemed safe in the clinics, one
concern with its use is the anergy induced in NKT cells after repeated systemic
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administration [102, 103].

Our lab, and others, has shown evidence that mucosal

administration in the form of intranasal or oral delivery of α-GalCer circumvents NKT cell
anergy, allowing for repeated activation and a stronger induced immune response
against co-administered antigens [104-107]. Although systemic administration of αGalCer showed a good safety profile in humans, mucosal route of administration has yet
to be tested in [108]. Nonetheless, interests in its use for anti-tumor efficacy remains
high. Multiple adjuvant related studies have shown enhanced immunity, and sometimes
even synergistic increases of immune response after the use of α-GalCer in combination
with a second adjuvant.

In particular, several studies have shown that α-GalCer

combined with a TLR agonist results in significantly higher DC activation, cytokine
release and overall immunity [109-111].

An example in our own lab, showed that

mucosal immunization with the combination of TLR-9 and α-GalCer is able to induce
robust antibody mediated immunity against HIV proteins [105]. Because of the robust
potential of α-GalCer and CpG-ODN as therapeutic adjuvants, I set out to investigate
whether mucosal intranasal administration of these two adjuvants harbored enhanced
therapeutic potential against HPV genital tumors.
Utilizing an orthotopic HPV vaginal tumor model, I tested the therapeutic potential
of these adjvuants by co-administering them with a set of HPV16 peptides.
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
Understanding how route of vaccination and adjuvants interact with one another
is critical for the development of a successful therapeutic vaccine. Despite the availability
of prophylactic vaccines against HPV, thousands of people who are ineligible/unable to
receive the vaccine are still at risk for HPV induced cancers. Therefore, there is still a
need to develop safe, yet effective treatment strategies that are not only easily
distributed, but are also cost-effective. Based on the reasons described in the previous
chapter, this dissertation investigates the potential of an intranasal therapeutic HPV
peptide vaccine employing the combination of adjuvants (α-GalCer and CpG-ODN) for
the treatment of HPV genital tumors. The peptides chosen for this vaccine were originally
identified in a study from our lab which realized that immune memory to these select
peptides correlated with recurrence free survival in women treated for cervical neoplasia
[112]. They include HPV16 Q19D (E744–62, QAEPDRAHVYNIVTFCCKCD); R9F (E749–
57,

RAHVYNIVTF); Q15 L (E643–57, QLLRREVYDFAFRDL); and V10 C (E649–58,

VYDFAFRDLC).
Therefore, I set out to investigate the following hypothesis:
Intranasal vaccination employing the combination of TLR9 and NKT cell ligands, (CpGODN and α-GalCer) will induce potent systemic and mucosal antigen-specific CD8 T cell
immunity, specifically at the female reproductive tract (FRT) to eliminate HPV genital
tumors. In order to address this hypothesis, I developed the following aims:
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•

Aim 1: Test whether intranasal vaccination employing the combination of
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response
to the co-administered antigen at multiple systemic and mucosal tissues

•

Aim 2: Determine whether intranasal delivery of HPV peptides together with the
adjuvant combination will be effective in treating established HPV+ vaginal
tumors.

•

Aim 3: Investigate whether the tumor location and route of vaccination will
influence therapeutic efficacy of the HPV peptide vaccine.
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CHAPTER 3. MATERIALS AND METHODS
3.1 Animals
Female C57BL/6J mice (6–10 weeks) were purchased from the Jackson
Laboratories (Bar Harbor, ME, USA) and were maintained in a pathogen-free
environment at the institutional animal facility accredited by the Association for
Assessment and Accreditation of Laboratory Animals Care International. Animals were
anesthetized with isoflurane for blood draws and hormonal administration, and with a
mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) administered by intraperitoneal
(IP) route for tumor implantation and N9 Treatment. All animal procedures were
conducted, including euthanasia in compliance with the University of Texas MD
Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC)
guidelines (Project ID: 00000858-RN02).

3.2 Cell Line and Reagents
The TC-1-luciferase (TC-1–Luc) tumor cell line is of lung fibroblast origin from
C57BL/6 mice that was transfected to stably express the E6 and E7 oncogenes of HPV16 as well as the H-Ras oncogene. This cell line additionally expresses firefly luciferase.
This cell line was a kind gift from Drs. T.-C. Wu and C. Hung (Johns Hopkins School of
Medicine, Baltimore, MD, USA). Cells were maintained in RPMI 1640 medium
supplemented with 10% heat inactivated FBS, 50 units/mL of penicillin–streptomycin,
and 50 µg/mL gentamycin.
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The four vaccine peptides Q19D (E744–62, QAEPDRAHVYNIVTFCCKCD); R9F
(E749–57, RAHVYNIVTF); Q15 L (E643–57, QLLRREVYDFAFRDL); and V10 C (E649–58,
VYDFAFRDLC), were purchased from Elim Biopharma (Hayward, CA, USA). Stock
solutions were prepared in a mixture of 10% dimethyl sulfoxide (DMSO) and 90% 1 ×
PBS at a concentration of 10 mg/mL. The α-GalCer adjuvant was purchased from
DiagnoCine (Hackensack, NJ, USA) and dissolved in DMSO (Sigma, St. Louis, MO,
USA) to prepare a stock solution at a concentration of 1 mg/mL. The CpG-ODN 1826
adjuvant was obtained from InvivoGen (San Diego, CA, USA) and dissolved in sterile
endotoxin free water to prepare a stock solution at a concentration of 10 mg/mL.
Endotoxin-free ovalbumin (OVA) protein was purchased from InvivoGen (San Diego, CA,
USA) and reconstituted at 20 mg/mL in PBS. Anti-CD8 blocking antibody was purchased
from BioXCell (Lebanon, NH, USA). The α4–1BB monoclonal antibody (LOB12.3) with
<1 endotoxin unit/mg was purchased from BioXcell (Lebanon, NH, USA) and
administered three times (350 µg/dose) via IP route on days 5, 8, and 11 after tumor
implantation as previously described [11]. The APC-labeled tetramer of H-2 Db-restricted
CD8 T cell epitope peptide R9F from the E7 oncoprotein of HPV-16, (E749–57,
RAHYNIVTF) was procured from the MHC tetramer production facility at Baylor College
of Medicine (Houston, TX) and was used for the detection and analysis of HPV antigenspecific CD8 T cell responses in different tissues by flow cytometry.
The estradiol was obtained by Sigma and diluted to a stock concentration of
1mg/ml in peanut oil (Sigma) by first dissolving 20mg estradiol in 1ml of 100% ethanol
(Sigma) and adding 19mls of peanut oil. Medroxyprogesterone acetate (Depo-Provera)
27

TITLE PAGE
was obtained from TCI and was used at a 10mg/mL solution in PBS. Nonoxyl-9 was
obtained from Abcam and stored in a de-humidifier chamber at room temperature.

3.3 In Vivo Tumor Experiments
For vaginal tumor experiments, female C57BL/6J mice (6–10 weeks) were first
hormonally synchronized by administering 0.1µg estradiol in peanut oil and 2mg
Medroxyprogesterone acetate (DepoProvera) in PBS subcutaneously on two
consecutive days (Fig. 2). One week later, cytology of vaginal smears was analyzed to
ensure mice were in diestrus as described by Decrausaz et al [113]. On the same
evening after collecting cytology samples, 20µL of 10% Nonoxyl-9 (N-9) was instilled in
the vaginal cavity of mice anesthetized with the ketamine/xylazine mixture and were left
over night.

The following morning, each mouse was again anesthetized with

ketamine/xylazine mixture and the vaginal cavity was washed five times with 80µL PBS
for the removal of all N-9. After washes were complete, 2 × 104 TC-1-Luc cells in sterile
PBS were instilled in the vaginal tract. Mice are kept in the supine position with their
lower halves slightly raised until anesthesia wears off. Treatment with N-9 induces microlesions in the vaginal epithelial walls, mimicking the naturally occurring micro-lesions in
humans necessary for HPV to access and infect basal epithelial cells. In this vaginal
tumor model, the micro-lesions generated provide an anchoring surface for the tumor
cells to embed within the vaginal epithelia. Tumor growth was monitored semiweekly
using Xenogen In Vivo Imaging System (IVIS) and expressed as average luminescent
signal in select Region of Interest (ROI) (p/sec/cm2/sr).
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For the experiments testing the flank tumor model, 2x105 TC-1 cells in sterile PBS
were injected subcutaneously in the left dorsal flank. Tumor size (length x width) was
measured 3 times per week using calipers and reported as tumor area (mm2).

Fig. 2. Vaginal tumor implantation and vaccination scheme.

Mice are

hormonally synchronized one week prior to tumor implantation, on days -8 and -7 by
administering Estradiole and Depo-provera subcutaneously 24 hours apart. One day
prior to tumor implantation vaginal washes are collected to ensure diestrus
synchronization and treated with 10% nonoxyl-9, overnight. The next morning, on day
0, the vaginal cavities are washed multiple times to remove the N-9, and 20,000 TC-1
Luc cells are then instilled into the vaginal cavity. Mice are immunized on days 5 and 11
after tumor implantation, and after successful tumor implantation has been confirmed,
and imaged weekly.

3.4 Vaccination Treatment
For intranasal vaccinations, five mice at a time were put under ketamine/xylazine
anesthesia and were maintained in the supine position while the listed doses of HPV
E6/E7 peptides (100 µg each) plus either α-GalCer (2 µg), CpG-ODN (10 µg), or the
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combination of both adjuvants were carefully administered in a drop-wise fashion using
a micropipette as previously described [114, 115]. More specifically, the total volume of
each vaccine (41ul for TVC, 42ul for TVA, and 43ul for TVAC) was divided into four doses
(ranging from 10.25ul for TVC to 10.75ul for TVAC) and each dose was administered in
a slow, dropwise fashion to each of the five mice, this allowed each mouse to rest in
between doses.
implantation.

Vaccinations were administered on days 5 and 11 post-tumor

For vaginal tumor-bearing mice, tumor size was first assessed by

luciferase imaging on day 5 to ensure successful tumor formation, and tumor bearing
mice were grouped according to tumor size in order to obtain similar average starting
tumor size per treatment.

Mice with a starting tumor size exceeding 20,000 ROI

(p/sec/cm2/sr) were evaluated separately and are referred to as “large vaginal tumors” in
the results section.

3.5 Isolation of Lymphocytes
For isolation and characterization of vaginal and flank tumor infiltrating
lymphocytes (TIL), mice were implanted with 3 × 104 TC-1–Luc cells in 10 µL, and 30x104
TC-1-Luc cells in 200µL of PBS/Matrigel mixture, respectively, at a 2:1 ratio for the
analyses of tumor-infiltrating leucocytes (TIL). Based on the prior survival analyses of
the different treatments/vaccinations, one week after the second vaccination was
selected as the time point to sacrifice mice for the TIL analyses studies. After CO2-based
euthanasia, each tumor was collected and diced into < ½ cm pieces and digested in a
mixture of 1 mg/mL collagenase D + 0.1 mg/ml DNase for 45 min at 37 °C before being
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passed through a 45 µm strainer. Lymphocytes were enriched through discontinuous
percoll gradient centrifugation and stained for flow cytometry analysis as previously
described [114, 116].
For isolation and characterization of lymphocytes from the female reproductive
tract (FRT), the vagina, uterus, and uterine horns were collected and cut into small
pieces. Diced tissue was then incubated in 5 mM EDTA for one hour, followed by
digestion with collagenase D (1 mg/mL) for 1h at 37 °C. Tissues were then passed
through a 45 µm strainer and purified by discontinuous percoll gradient centrifugation
[117].
Lastly, for isolation of lymphocytes from other lymphoid organs, including spleen,
CLN, ILN, these soft tissues were directly passed through a 45um strainer. Splenocytes
were pelleted and treated with red blood cell (RBC) lysis solution (ACK from Thermo
Fisher) for one minute before being washed with and re-suspended in cell media.

3.6 CD8 Depletion
For in vivo CD8 depletion, mice were administered 100 µg of aCD8 mAb from
BioXCell (Lebanon, NH, USA) via the intraperitoneal (IP) route one day prior to the first
vaccination dose, and every three days after that until the completion of the experiment.
The CD8 depletion was monitored in the blood throughout the course of the experiment
as described in the results section.
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3.7 NK Depletion
For in vivo NK cell depletion, mice were administered 200 µg of PK136 mAb from
BioXCell (Lebanon, NH, USA) via the intraperitoneal (IP) route one day prior to the first
vaccination, and once every week until the completion of the experiment.

Proper

depletion of NK cells was monitored in the blood throughout the course of the experiment
as described in the results section.

3.8 Adoptive Transfer of OT-I Cells
The ovalbumin (OVA)-specific OT-I TCR transgenic (Tg) CD8 T cells were
obtained from lymph nodes of untreated OT-I mice (CD45.1+) and 1 × 106 cells were
transferred to congenic C57BL/6J mice (CD45.2+) intravenously in 200 µL of sterile PBS.
Mice were immunized intranasally with 5 µL of reconstituted endotoxin free OVA alone
or in the presence of α-GalCer and/or CpG-ODN adjuvants one day after adoptive
transfer and sacrificed one week after vaccination.

3.9 Flow Cytometry Analysis
Single cell suspensions from tumors, tissues or PBMC were fixed using the
Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA) and
then stained with antibodies to different surface and intracellular markers obtained from
Biolegend (San Diego, CA, USA), BD Biosciences (Franklin Lakes, NJ, USA),
eBioscience (San Diego, CA, USA), and Life Technologies (Carlsbad, CA, USA). The
CD1d tetramer reagent specific for NKT cells was obtained from NIH tetramer core facility
32

TITLE PAGE
at Emory University (Atlanta, GA, USA). Flow cytometry data were collected on a fivelaser, BD Biosciences LSR II cytometer and analyzed using FlowJoTM Software for
Windows, version 10 (Becton, Dickinson and Company, Ashland, OR, USA).

3.10 Statistical Analysis
All statistical analyses were performed using Graphpad Prism version 8 for
Windows. Statistical significance was determined using either ordinary one-way ANOVA
plus multiple comparisons, or the Brown–Forsythe and Welch ANOVA plus multiple
comparisons to test for differences between groups. Statistical significance for survival
analysis was calculated using the Mantel–Cox log rank test where indicated. p value of
<0.05 was considered significant in each comparison. All figures depict average data
values with SEM.
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CHAPTER 4. RESULTS
4.1. Introduction:
We previously reported that in the TC-1 luc preclinical HPV vaginal tumor model,
therapeutic vaccination with synthetic peptides corresponding to the E6 and E7
oncoproteins of HPV-16 and α-GalCer adjuvant delivered by the intranasal route in mice,
reduced tumor growth rate but required α4–1BB antibody immunotherapy to induce
sustained tumor regression and significant survival advantage [114]. The anti-tumor
efficacy from this combination of intranasal vaccination and immunotherapy correlated
with the induction of highly cytotoxic CD8 T cells expressing multiple granzyme effector
molecules.
Toxic side effects and the high costs associated with immunotherapy, however,
are concerns with this treatment approach [118-120]. Therefore, I tested an alternate
strategy for effective induction of antigen-specific CD8 T cell response by incorporating
the toll-like receptor (TLR) 9 ligand CpG-ODN along with α-GalCer, as diverse acting,
but clinically relevant adjuvants.
The rationale for the adjuvant selection is that α-GalCer adjuvant activates antigen
presenting cells (APCs) through the stimulation of NKT cells, resulting in the release of
cytokines such as IFN-γ and IL-2 which act back on the APCs, inducing maturation and
increasing antigen presentation [121]. Meanwhile CpG-ODN directly stimulates APCs
by binding to TLR-9 present on the cell surface, inducing antigen-specific CD8 T cell
immunity [122]. These two activation mechanisms recognized as alternative (NKTmediated), and classical licensing (mediated by TLR-ligands) of APCs, are expected to
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activate distinct chemokine signaling to recruit diverse sets of naïve CD8 T cells for
enhanced adaptive immunity [26].
I hypothesized that intranasal vaccination employing the combination of TLR9 and
NKT cell ligands, (CpG-ODN and α-GalCer) will induce potent systemic and mucosal
antigen-specific CD8 T cell immunity, specifically at the female reproductive tract (FRT)
to eliminate HPV genital tumors.
In order to test this hypothesis, I developed the following aims:
•

Aim 1: Test whether intranasal vaccination employing the combination of
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response
to the co-administered antigen at multiple systemic and mucosal tissues

•

Aim 2: Determine whether intranasal delivery of HPV peptides together with the
adjuvant combination will be effective in treating established HPV+ vaginal
tumors.

•

Aim 3: Investigate whether the tumor location and route of vaccination will
influence therapeutic efficacy of the HPV peptide vaccine.

4.2: (Aim 1) Test whether intranasal vaccination employing the combination of
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response
to the co-administered antigen at multiple systemic and mucosal tissues
In this section, I first addressed the hypothesis that intranasal vaccination utilizing
the combination of α-GalCer with CpG-ODN, relative to each adjuvant alone, will result
in higher induction of CD8 T cells specific to the co-administered antigen at multiple
systemic and mucosal tissues, including the FRT (Aim 1.1). I then addressed the
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hypothesis that the resulting CD8 immune response will exhibit stronger cytolytic
characteristics in mice receiving the combination of adjuvants in comparison with either
adjuvant alone.
Data obtained from these studies were included in recently published manuscript
(Seirra et al. 2020)
4.2.1 Determine the potential of the intranasal vaccination using α-GalCer and/or CpGODN adjuvants for promoting trafficking of CD8 T cells to the FRT (Aim 1.1)
In order to determine whether the proposed intranasal therapeutic peptide
vaccination strategy will be effective to treat established HPV genital tumors, I first tested
for successful induction of cellular immunity to the FRT. Specifically, I investigated
whether vaccination using the combination of adjuvants, relative to each adjuvant
individually, will increase CD8 T cell responses at the FRT, in particular antigen specific
CD8 T cells. For this, I have adapted the ovalbumin (OVA)-specific OT-I TCR transgenic
(Tg) CD8 T cells as a model system because of the convenience and efficiency to monitor
induction and localization at multiple tissue sites.
In this approach, mice were adoptively transferred with 1x106 OT-I cells
intravenously one day prior to intranasal administration of endotoxin-free ovalbumin
(OVA) alone or along with α-GalCer, or CpG-ODN, or the combination of α-GalCer and
CpG-ODN. Mice were sacrificed one week after for flow cytometry analysis of isolated
lymphocytes from the spleen, and FRT along with vaccine-draining cervical lymph nodes
(CLN), FRT-draining inguinal lymph nodes (ILN). Data shown in Fig. 3A illustrates the
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percentages of OT-I cells (CD45.2+ and Va2+) in each of the different groups of mice and
clearly establishes the effectiveness of the vaccine containing the two adjuvants, αGalCer and CpG-ODN, together verses each adjuvant alone in terms of significantly
higher percentage of OT-I cells in each of the tissues analyzed.
These data demonstrate that intranasal immunization with OVA using either αGalCer or CpG-ODN increased the percentage of OT-1 cell in the spleen, cervical lymph
nodes (CLN), inguinal lymph nodes (ILN) and the female reproductive tract (FRT) when
compared to mice receiving OVA alone.

Immunization using the combination of

adjuvants further increased the percentages of OT-I cells significantly, in all the tissues
examined (Fig 3B-E).
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Figure 3. Intranasal immunization utilizing the combination of α-GalCer and CpGODN adjuvants induces significant increase of antigen specific CD8 T cells in
systemic and mucosal tissues. Adoptively transferred OT-I cells were analyzed by
flow cytometry in spleen, FRT, CLN, and ILN one week after intranasal immunization
with OVA alone or in combination with α-GalCer and CpG-ODN adjuvants individually or
together. Representative gating strategy from the spleen is shown (A); OT-I cells are
gated from CD8+ cells as double positive for CD45.1 and Vα2 (left panels of B-E).
Representative flow plots of OT-1 cells in each tissue are shown in B-E (left panels of BE), and average values for the frequencies in each tissue are summarized in the bar
graphs in the far right panels for each tissue. Statistical significance was calculated using
ordinary one-way ANOVA with multiple comparisons and the Brown–Forsythe and Welch
ANOVA with multiple comparisons, p < 0.05 (*), p < 0.005 (**), p < 0.0005 (***), p <
0.00005 (****).
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4.2.2 Determine the therapeutic potential of CD8 T cells generated after intranasal
delivery of α-GalCer and CpG-ODN, alone or in combination at both systemic and
mucosal tissues (Aim 1.2)
Although infiltration of CD8 T cells to the tumor is generally considered indication
of positive antitumor efficacy [123-125], functionality, in terms of killing capacity of the
tumor infiltrating CD8 T cells is important for effective tumor eradication. Therefore, I
next examined the functionality of the antigen specific CD8 T in the spleen and FRT of
vaccinated mice by using intracellular cytokine (ICC) staining for Granzyme B
expression, a marker for cytotoxicity.
Results from this analysis indicate that immunization with OVA plus the
combination of α-GalCer and CpG-ODN produced significantly higher percentages of
Granzyme B expressing antigen specific CD8 T cells (OT-1 cells), as well as the total
CD8 T cell population in the spleen and FRT (Fig. 4A, B, respectively).
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Fig. 4. Intranasal immunization employing the combination of α-GalCer and CpGODN adjuvants significantly increases the frequencies of functional antigenpresenting cells as well as overall CD8 T cells in the spleen and FRT. Adoptively
transferred OT-I cells were analyzed by flow cytometry in the spleen and FRT one week
after immunization with OVA alone, or with the combination of α-GalCer and CpG-ODN.
Average values for the frequencies of OT-I cells expressing GzmB (A), and overall
frequency of CD8 T cells expressing GzmB (B) in the spleen and FRT of mice were
compared between the treatments using t-test, p < 0.005 (**), p < 0.0)05 (***).
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These results demonstrate that intranasal immunization using the combination of
α-GalCer and CpG-ODN adjuvants is an effective strategy to induce a robust and
functional immune response in both systemic tissues, such as the spleen, and in the
mucosal tissues, like FRT.
Based on these results, I tested whether therapeutic HPV peptide vaccination
employing the combination of α-GalCer and CpG-ODN adjuvants will induce anti-tumor
efficacy against HPV genital tumors.

4.3. (Aim 2) Determine whether intranasal delivery of HPV peptides together with
the adjuvant combination will be effective in treating established HPV+ vaginal
tumors.
The therapeutic vaccine comprised of synthetic peptides corresponding to the E6
and E7 oncoproteins of HPV-16, immunity which correlated with disease-free survival in
women treated for CIN2/3 neoplasia[112]. Therefore, I tested the efficacy of vaccination
using these peptides along with α-GalCer and/or CpG-ODN adjuvants for therapeutic
efficacy in the orthotopic HPV vaginal tumor model. For simplicity sake the different
vaccine compositions from here on out will be referred to as therapeutic vaccine
containing α-GalCer (TVA), therapeutic vaccine containing CpG-ODN (TVC), and
therapeutic vaccine containing α-GalCer and CpG-ODN (TVAC).
Some of the results from this following section were also reported in a recently
published manuscript (Sierra et. Al 2020)
In the orthotopic HPV vaginal tumor model, mice were hormonally synchronized
and implanted with 20,000 TC-1Luc cells as described in the methods. Five days after
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tumor induction, mice were imaged to ensure successful implantation of the tumor and
sorted in order to ensure a similar average starting tumor size in the control group as
well as in each of the treatment groups (TVA, TVC, or TVAC). Therapeutic vaccines
were administered intranasally on days 5 and 11 after tumor implantation. Tumor size
was monitored using the In Vivo Imaging System (IVIS) 200 in the institutional Small
Animal Imaging Facility (SAIF) and reported as average radiance (p/s/cm2/sr) within a
2x2cm circular region of interest (ROI) placed over the FRT on the imaging software
Living Image.
Tumor size was measured on a weekly basis and survival was charted up to 90
days post-tumor implantation (Fig. 5A, 5B). Mice treated with TVA or TVC exhibited
tumor regression in a minor subset (20% and 33% respectively), but overall significantly
better survival when compared to the untreated mice, or mice treated with the adjuvants
alone. On the other hand, the majority (85%) of mice treated with TVAC, showed
complete tumor regression, and significantly higher survival rates in comparison to either
TVA or TVC treated groups.
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Fig. 5. Intranasally administered TVAC is effective at treating established
orthotopic HPV vaginal tumors.

Female C57BL/6J mice (n = 10 to 22) were

hormonally synchronized and challenged with 2 × 104 TC-1-Luc cells into the vaginal
cavity. Intranasal vaccinations using HPV peptide vaccine formulated with either αGalCer, CpG-ODN, or both α-GalCer and CpG-ODN (TVA, TVC, or TVAC, respectively)
were administered on days 5 and 11 after tumor cell implantation; control groups included
untreated mice, or mice immunized with the mixture of adjuvants without peptides
(adjuvants alone). Survival analysis was recorded between each treatment group as well
as the appropriate controls (A). Tumor size was measured using luciferase expression
(ROI units) and plotted over time. The numbers of mice with complete tumor regression
over total per group (minimum 10 mice per group) are shown in each panel for the
different treatment groups (B). Significance in survival proportions was measured using
the log-rank test. p < 0.05 (*), p < 0.00005 (****),
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4.3.1. Characterization of antitumor immune responses in mice treated with the
different vaccines
Because positive modulation of the tumor micro-environment, specifically
enhanced levels of tumor infiltrating CD8 T cells have historically correlated with better
treatment-mediated outcome in patients [126], I analyzed the tumor infiltrating leukocytes
(TILs) in mice with vaginal orthotopic HPV tumors after the various treatments on day 18
post-tumor implantation.

This time point was chosen based on the substantial

differences in tumor size evident between treatment groups (Fig. 6A).
The TILs were isolated as described in the methods section and analyzed by polychromatic flow cytometry using 14 different antibodies to detect various cell surface and
intracellular markers. A typical gating strategy used for the flow cytometry analyses is
shown in Fig. 6B.
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Fig. 6. Strategy for characterization of tumor infiltrating lymphocytes. Tumor
bearing mice were sacrificed one week after the second vaccination (V2) for
characterization of tumor infiltrating leukocytes. Tumor size significantly varies at this
time point and thus was chosen to distinguish immunological differences between
treatment groups (red oval) (A).

A generalized gating strategy is shown to depict

characterization of the tumor infiltrating leukocytes (B). The first set of gates were set to
detect cells based on size and granularity, followed by exclusion of dead cells and
detection of CD45+ leukocytes. Subsequently, the live CD45+ cells were differentiated
as T cells based on the expression of CD3, followed by further characterization of
different CD4+ and CD8+ T cells subsets along with functional markers.
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We found that TVAC treated mice showed consistently higher frequencies of CD8
T cells when compared to those treated with TVA and TVC, as well as the untreated
control groups (Fig. 7A). More importantly, significantly higher levels of antigen specific
CD8 T cells were detected using the HPV16 E7 peptide tetramer in the TVAC treated
mice, relative to other groups (Fig 7B). Furthermore, granzyme B (GzmB) positive CD8
T cells as well as E7-specific CD8 T cells, representative of cytotoxic functionality, were
found at higher frequencies in TVAC treated mice, relative to those in all other groups
(Fig. 5A, 5B, left panels, respectively).
In addition to the CD8 T effector cells, I also investigated the frequencies of
suppressor cell populations (MDSCs and Tregs) within the tumor. Overall, a trend for
higher density of CD8 T cells (measured in terms of cells/tumor weight) was observed in
mice receiving TVAC when compared to TVA, TVC, or untreated controls, while the
suppressor cells showed the opposite trend (Fig. 7C). This translated into highest
proportion of CD8 T cells relative to Tregs and MDSC combined in the TVAC treated
animals, relative to those in other groups (60% CD8 in TVAC vs ~40% in TVA/TVC) as
shown in the pie charts (Fig. 7D).
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Fig. 7. Increased frequencies of effector CD8 T cells, relative to suppressor cells
are correlates of protection by TVAC in mice with HPV genital tumors. Highest
percentages of total and cytotoxic (GzmB+) populations of CD8 T cells as well as HPV
E7 antigen specific CD8 T cells were observed within the tumors of TVAC treated mice,
relative to those treated with TVA and TVC or untreated controls (B). Densities of CD8
T cells and suppressor cells (Tregs and MDSCs) in the tumors of mice in the different
groups were plotted numbers per tumor weight (C). Individual frequencies of tumor
infiltrating CD8 T cells, Tregs, and MDSCs among the three populations together reveal
the dominance of CD8 T cells over the two suppressor together in the tumors of TVAC
treated mice, relative to other groups (D). Statistical significance was calculated using a
one way ANOVA, p<0.05 (*), p<0.005 (**), p<0.0005 (***)
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4.3.2. Comparative analyses of immune correlates for antitumor efficacy between
TVAC and the combination of TVA and anti-4-1BB immunotherapy
In comparing the antitumor efficacy of TVAC with TVA plus anti-4-1BB treatment
(TVA + ɑ4-1BB) against established vaginal TC-1 tumors [114], there was no observed
significant difference between these two treatments in terms of tumor regression and
tumor-free survival (Fig. 8A). Therefore, I next investigated, by flow cytometry, the tumor
infiltrating lymphocytes isolated from mice treated with TVA + ɑ4-1BB and TVAC one
week after the second vaccination. Although comparable levels of total and HPV E7
antigen specific CD8 T cells were induced in both treatment groups (Fig. 8B), we did not
detect the highly cytotoxic CD4 and CD8 T cell subsets called ThEO, and TcEO cells,
respectively, in TVAC treated mice, which were the defining feature of the efficacy of the
TVA + ɑ4-1BB treatment (Fig. 8C, 8D). We observed a trend for higher frequencies of
total and antigen-specific CD8 T cells expressing Granzyme B or IFN-γ in TVAC treated
mice, but the differences did not reach significance (Fig. 8E). Mice treated with TVA +
ɑ4-1BB, however, did show significantly higher levels of liver enzymes in the bloodAspartate transaminase (AST) and alanine aminotransferase (ALT)- which serve as
indicators of systemic toxicities attributed to immune checkpoint therapy, relative to those
receiving TVAC [119, 120, 127-129].
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Fig. 8. Comparable antitumor efficacy for TVAC and TVA + ɑ4-1BB treatments.
Female C57BL/6J mice with vaginal TC-1 tumors were treated with TVAC or TVA + ɑ41BB as described in the methods and monitored for survival (A). TIL analysis was carried
out to compare CD8 T cell frequencies as well as antigen specific CD8 T cells (B). TcEO
cells (classified as EOMES+ KLRG-1+ CD8 cells were found to be a unique feature of
TVA + a4-1BB treatment (C, D). Functionality of overall CD8 T cells (E, G) and HPV E7
antigen specific CD8 T cells (F) were also compared between these two treatments.
Liver enzyme levels were recorded in blood three days after each vaccination and
reported as units of aspartate transaminase (AST) or alanine aminotransferase (ALT)
per liter (L). Significance in survival proportions was measured using the log-rank test;
ns=not significant.

Statistical significance between different treatment groups was

calculated using a One-Way ANOVA with multiple comparisons. p<0.00005 (****),
p<0.0005 (***), p<0.005 (**), p<0.05 (*).
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4.3.3. Investigate the contribution of CD8 T cells for the anti-tumor efficacy of TVAC
treatment
Since the data in Fig. 7 showed induction of CD8+ T cells as an important correlate
for the efficacy of TVAC, I tested weather and to what extent depletion of CD8 T cells
would abrogate the protection. Vaginal TC-1 tumor-bearing mice treated with TVAC
were administered an isotype control or anti-CD8 depletion antibody every three days
starting one day prior to tumor induction, and untreated mice served as an additional
control (Fig. 9A). Blood collected over time was analyzed to confirm depletion of CD8 T
cells, Day 17 post tumor induction flow plots are depicted as representative graphs (Fig.
9B). I observed near complete depletion of CD8 T cells (99.6% decrease relative to
control) in mice receiving the CD8 depletion antibody, which correlated to significant
abrogation of the anti-tumor efficacy of TVAC in terms of significantly lower survival due
to tumor growth when compared to the isotype control (Fig. 9C, 9D).
These results indicate that the CD8 T cell response generated by the intranasal
administration of TVAC is essential for tumor clearance.

55

TITLE PAGE

56

TITLE PAGE
Fig. 9. CD8 T cells are essential for TVAC efficacy against vaginal TC-1 tumors in
mice. Tumor bearing mice were vaccinated intranasally as previously described with
TVAC on days 5 and 11, and either treated with a CD8 depletion antibody or IgG control
once every three days. An untreated group served as an additional control (A). CD8
depletion was monitored in the blood over the course of multiple time points using FACS.
Representative FACS plots gated on live CD3 population show complete CD8 depletion
only in mice receiving depletion antibody at one week post-tumor implantation (B).
Tumor growth and survival were monitored in mice and plotted over time (C).
Significance in survival proportions was measured using the log-rank test. p < 0.005 (**),
p>0.05 (ns).
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4.3.4-Role of NK and NKT cell subsets in TVAC efficacy
The composition of TVAC includes the adjuvant α-GalCer known to promote
antigen presentation via the activation of NKT cells, which are important for innate
immune surveillance via direct cytotoxic functions. Therefore, I investigated their role in
the observed efficacy of TVAC against the vaginal TC-1 tumor model.
NKT cells are classified into at least two main subsets, type 1 NKT cells and Type
2 NKT cells. Type 1 NKT cells, which are more commonly referred to as invariant NKT
(iNKT), express the invariant Vα14-Jα18 in mice and Vα24-Jα18 in humans, and are
generally identified in flow cytometry as CD3 intermediate and NK1.1+[130]. They are
strongly reactive to α-GalCer and can be identified using α-GalCer loaded CD1d tetramer
reagents.
Type 2 NKT cells, however, are described as the more evasive population of NKT
cells due to the fact that they do not express a semi-invariant TCR chain like the iNKT
cells and can’t be identified with α-GalCer loaded CD1d tetramer [131], instead they have
diverse TCRs but are still CD3+, NK1.1+. Under normal conditions, these cells harness
anti-inflammatory capabilities, however, recent studies have indicated that CpG-ODN
can shift the capabilities of type 2 NKT cells to an inflammatory response with anti-tumor
capabilities [132]. Based on this information, I hypothesized that TVAC comprising both
α-GalCer and CpG-ODN adjuvants may be engaging type 2 NKT cells for their potential
contribution towards the observed anti-tumor efficacy.
Interestingly, one of the primary reasons early clinical trials using α-GalCer
showed dampened results in humans is due to the reduced frequencies of iNKT cells in
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comparison to mouse models[108]. Given that type 2 NKT cells are more prominent than
iNKT in humans [133], engagement of these cells could potentially lead to better clinical
outcomes. By gating on CD3+NK1.1+ cells in the flow cytometry analyses, I attempted
to identify these cell within the TC-1 tumors of untreated mice and those administered
the different vaccine formulations (Fig 10A).
Tumor bearing mice were treated with TVA, TVC, or TVAC and sacrificed three
days after the second dose. This time point was chosen due to the rapid response of
NKT cells after intranasal stimulation where the peak response is typically at three days
[107]. I observed slight increase in the levels of iNKT cells (Type 1 NKT cells) in the
tumors of TVAC and TVA treated mice, (Fig 10B) with TVAC treated mice exhibiting the
highest number of IFN-γ expressing iNKT cells among the different groups of mice(Fig.
10C). The frequency of type 2 NKT cells increased within the tumor in TVC treated
groups, however, no differences in the numbers of IFN-γ positive cells was recorded in
the tumors of different groups of mice examined (Fig 10D, 10E).
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Fig. 10. Detection and characterization of NKT cell subsets in the vaginal TC-1
tumors of vaccinated mice. Tumor bearing mice were treated on days 5 and 11 as
previously described with either TVA, TVC, or TVAC. Three days after the second
vaccination, lymphocytes were collected and analyzed according to the gating strategy
shown (A). The CD1d tetramer positive cells were classified as type I NKT (iNKT) cells,
while CD1d tetramer negative were classified as type 2 NKT cells. Frequencies of each
subset and functionality in terms of IFN-γ expression are shown (B-E).
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In order to evaluate the potential contributions of NK and NKT cells subsets for
the anti-tumor efficacy of TVAC, I conducted a NK depletion study. Because there is no
single antibody to deplete specifically the NKT cells, I used the PK136 antibody that
depletes both NK and NKT cells subsets. The tumor bearing mice were treated with
TVAC as previously described, on days 5 and 11, along with IP administration of the
PK136 antibody or a control IgG one day prior to each TVAC treatment (days 4 and 10
post-tumor implantation) and weekly thereafter.

Blood was collected weekly and

analyzed to ensure NK depletion. Representative flow plots depict specific NK depletion
in the blood and are plotted as averages per antibody treatment (Fig. 11A, 11B). Survival
and average tumor growth were monitored over time (Fig. 11C, 11D), and individual
mouse tumor growth is also shown (Fig. 11E)
Despite near complete depletion of NK cells subsets, I observed only marginal
decrease in TVAC-mediated protection, in terms of tumor growth and survival
percentage. These results suggest minor contribution by the NK and NKT cells subsets
towards the observed antitumor efficacy of TVAC against vaginal TC-1 tumors, the
genital HPV tumor model.

61

TITLE PAGE

62

TITLE PAGE
Fig. 11. Depletion of NK cells does not significantly influence the efficacy of TVAC
against orthotopic vaginal TC-1 tumors.

Vaginal tumor bearing mice were

administered either PK136 antibody or control IgG via the IP route, one day prior to each
vaccination, and weekly thereafter. TVAC was administered intranasally as previously
described on days 5 and 11. Blood was analyzed weekly to ensure proper NK depletion,
and representative flow plots as well as numeric summaries are shown (A, B). Mice were
monitored for survival (C) and imaged weekly to monitor tumor growth (D, E). Statistical
significance was calculated using a two-sided t-test, p<0.05(*)
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4.4. (Aim 3) Investigate the effect of tumor location and route of vaccine
administration on the therapeutic efficacy of TVAC
Based on the potent antitumor efficacy observed for TVAC administered by the
intranasal route against established HPV orthotopic tumor model of vaginal /TC-1
tumors, I tested whether the vaccine is equally efficacious against subcutaneously
implanted flank tumors (aim 3.1), and whether the vaccine will be effective if delivered
by systemic subcutaneous route (aim 3.2).
4.4.1 Determine the efficacy of intranasally administered TVAC against subcutaneous
HPV tumors.
Up to 23% of Stage IV HPV genital cancers are reported to spread into other parts
of the body [134], therefore I set out to determine whether intranasally administered
TVAC would also be effective in treating tumors at non-mucosal location by injecting the
TC-1 tumor cells subcutaneously on the flank.
Naïve female C57Bl6/J mice were implanted with 200,000 TC-1 Luc cells
subcutaneously in the flank, and immunized on days 5 and 11 as described in the
methods. Mice were administered either TVA, TVC, or TVAC by the intranasal route and
monitored for tumor growth and survival (Fig. 12A). Tumor size was measured three
times per week using calipers and plotted as area (mm2) over time.
I observed nearly 30% of the TVAC treated mice with subcutaneous flank tumors
exhibit tumor regression and improved survival relative to any other treatment (Fig. 12B).
This level of antitumor efficacy for the intranasal TVAC treatment is lower than the 70%
observed for mice with mucosal vaginal tumors (Fig.7).
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Fig. 12. Intranasal delivery of TVAC shows limited efficacy in subcutaneously
implanted TC-1 tumors. Groups of 57BL/6 female mice were injected with 2x106 TC1Luc cells subcutaneously on the flank and treated by the intranasal route with either
TVA, TVC, or TVAC on days 5 and 11 after tumor induction (A), a separate group of
untreated mice served as control group. Survival rates (B), and tumor growth were
monitored over time (C) and also expressed as individual mice in each group (D).
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In order to determine the immune correlates for the observed partial protection of
TVAC against the subcutaneous tumors, tumor infiltrating lymphocytes were collected
for flow cytometry analysis one week after the last treatment.
The frequencies of overall and antigen specific CD8 T cells were significantly
increased in the tumors of mice treated with TVAC when compared to untreated control
mice, similar to the data from the analyses of TILs from mice with vaginal tumors (Fig.
13A, 13B). Furthermore, granzyme B expressing total and antigen specific CD8 T cells
were also at higher frequencies in mice receiving TVAC, relative to that in the untreated
mice (Fig.13C, 13D). This data indicates that intranasal administration of TVAC is
effective at inducing a robust immune response in flank tumors, but was insufficient to
afford the level of tumor regression matching that in the vaginal tumor model (Fig. 7).
Therefore, I investigated for changes in the frequencies of immune suppressive Tregs
and MDSCs and compared the effector to suppressor cell ratios in the different groups
of mice treated for subcutaneous flank tumors. Although the CD8 T cells in the flank
tumors were found at higher percentages in the TVAC treated mice when compared to
the untreated and TVC treated mice, the density of CD8 T cells in the flank tumors were
similar in TVA and TVAC treated mice (Fig. 13E). Treg and MDSC populations were
also similar in TVA and TVAC groups, with lower levels found in the untreated and TVC
treated groups (Fig. 13F, 13G). Unlike the trend we saw in the TVAC administered mice
with vaginal tumors, a stronger CD8 T cell response was not observed when compared
to the suppressor cell populations, resulting in no improvement of the ratio of effector
(CD8 T cells) to total fractions of suppressor cells (Tregs and MDSCs) (Fig. 13H).
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Fig. 13. Tumor infiltrating lymphocytes in the flank tumors of mice treated with
TVAC by the intranasal route. Groups of 57BL/6 female mice were injected with 2x106
TC-1Luc cells subcutaneously on the flank and treated by the intranasal route with either
TVA, TVC, or TVAC on days 5 and 11 after tumor induction (A), and a separate group of
untreated mice served as control group. Single cell suspensions from flank tumors
collected one week after completion of the last immunization were analyzed by flow
cytometry. Frequencies of total and antigen specific CD8 T cells (A and B) as well as
respective functional subsets (C and D) were enumerated in different groups of mice.
Densities of CD8, Treg, and MDSCs populations in terms of numbers of cells/tumor
weight were plotted (E). The ratios of CD8 to cells to each of the suppressor cell subsets
as well as total suppressor cells were shown (F). Statistical significance was calculated
using one-way ANOVA, p < 0.05 (*), p < 0.005 (**), p < 0.0005 (***), not significant (ns).
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Early diagnosis and treatment of tumors offers higher rates of survival [135, 136].
It is therefore possible that delayed treatment would most likely results in the
accumulation of higher numbers of immune suppressive cells, including MDSCs and T
regulatory cells in the tumor microenvironment. Because the experimental protocol for
subcutaneously implanted flank tumors involved injection of a higher dose of tumor cells
(200,000), relative to that for the vaginal tumors (20,000), I hypothesized bigger flank
tumor size prior to the start of the treatment/vaccination regimen (day 5) allowing for
greater accumulation of immune suppressive cells resulting in the observed lower
efficacy of the therapeutic vaccine, TVAC, relative to that in the vaginal tumor model
studies.
To test this hypothesis, specifically MDSC accumulation as a major reason for the
reduced efficacy of TVAC against flank TC-1 tumors, I utilized anti-Gr-1 antibody to
deplete MDSCs. The antibody was administered by the intraperitoneal route weekly,
starting two days after tumor implantation to mice treated with TVAC and control
untreated mice (Fig. 14A). Blood was analyzed by flow cytometry at several time points
to ensure depletion of MDSCs (Fig 14B, 14C). Tumor growth and survival were recorded
over time (Fig. 14D, 14E, 14F).
I observed that depletion of the MDSCs did not provide any significant advantage
in survival or reduction of tumor size/growth rate in either the TVAC treated or control
groups of mice. This indicates that MDSC accumulation prior to treatment may not be
contributing to the diminished TVAC efficacy in the flank implanted TC-1 tumors.
Alternately, Tregs and or the combination of MDSC and Tregs together directly or
68

TITLE PAGE
through soluble factors could be at overwhelmingly higher frequencies/densities in the
tumor for the total and antigen-specific cytotoxic T cell populations to impart antitumor
efficacy.
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Fig. 14. MDSCs depletion fails to increase efficacy of TVAC in subcutaneously
implanted flank TC-1 tumors.

Tumor bearing mice were treated with anti-GR-1

antibody (IP) weekly, starting two days after tumor implantation followed by TVAC (IN)
on days 5 and 11 as previously describe in the methods section (A). Proper MDSC
depletion was ensured via flow cytometry at several time points throughout treatment;
representative gating strategies are shown for the detection of MDSCs in the blood and
are shown for each treatment group (B, C). Tumor growth was monitored over time (D,
E), and survival was recorded (F). Significance in survival proportions was measured
using the log-rank test. P>0.05 (ns).
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Thus, the timing of vaccine administration with respect to tumor burden could
potentially be a confounding factor for the weaker immune protection by the TVAC. In
fact, a comparison of tumor size determined by the luciferase expression based imaging
analyses, revealed a significantly larger starting size for the subcutaneous flank tumors
relative to the vaginal tumors correlating with the relative differences observed for the
vaccine-mediated efficacy (Fig. 15B). Because subcutaneously implanted tumors with
less number of cells in the inoculum tend to spontaneously regress in immune competent
mice, reducing the number of tumor cells for initiating the tumor growth was not an option.
Therefore, I tested initiating vaccine treatment on day 1 after subcutaneous injection of
tumor cells, followed by the second dose delivered on day 5, thus keeping the intervals
between the two vaccinations the same as in the previous experiment (Fig. 15 A).
Importantly, the size of the subcutaneously growing flank tumors at day 1 was
comparable (based on luciferase expression) to that of vaginal tumors at day 5 (when
the immunization was initiated) (Fig. 15B). In this vaccination regimen, TVAC-treated
mice exhibited effective control of tumor growth in about 75% of mice with significant
survival and these outcomes are comparable to that seen for vaginal tumors treated with
this vaccine TVAC (Fig. 15 C, 15D). Furthermore, TIL analysis revealed that treatment
of the smaller subcutaneously flank tumors treated on day 1 resulted in significantly
higher concentrations of CD8 T cells (per gram of tumor), when compared to that in the
larger flank tumors (treated on day 5) (Fig. 15E).
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Fig. 15. Flank and vaginal tumors matched for pre-treatment size are responsive
to intranasally delivered TVAC. Groups of C57BL/6 female mice were injected with
2x106 TC-1Luc cells subcutaneously on the flank and treated by the intranasal route with
either TVA, TVC, or TVAC on days 1 and 6 post-tumor induction (A). Vaginal tumor size
on day 5 compared to that of flank tumors on days 1 versus day 5 (B). Tumor bearing
mice were followed for survival and tumor growth (C, D). Density of CD8 T cells in the
tumor one week after second dose of TVAC are compared between mice with smaller
flank tumors receiving TVAC treatment on day 1 (small SC TVAC) versus the in mice
with larger flank tumors that began treatment on day 5 (Large SC TVAC) (E). Statistical
significance was calculated using One-Way ANOVA test with multiple comparisons.
p>0.05 (ns), p<0.005 (**), p<0.00005 (****).
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4.4.2. Determine the importance of mucosal intranasal route of immunization for the
efficacy of TVAC against vaginal TC-1 tumors (Aim 2.2)
The mucosal immune system is a compartmentalized portion of the overall
immune system. Because HPV is primarily transmitted via mucosal surfaces, a major
rationale for adapting mucosal intranasal route of immunization is to not only induce
robust antigen specific CD8 T cell response, but also to promote their trafficking to the
female reproductive tract for efficient tumor clearance.

While data obtained from

intranasal delivery of TVAC demonstrated strong efficacy against vaginal HPV tumors, it
is not clear whether systemic route of vaccine administration would be inferior or equally
effective at protecting against vaginal HPV tumors.
To begin testing this, the OT-I transgenic mouse model was adapted to first
monitor distribution of antigen specific CD8 T cells across multiple systemic and mucosal
tissues after systemic intramuscular immunization regimen. A total of 1x106 OT-I cells
were adoptively transferred into congenic C57Bl/6 mice followed one day later by
treatment with OVA plus the combination of α-GalCer and CpG-ODN adjuvants either by
the mucosal intranasal or systemic intramuscular route. Frequencies of OT-I cells were
determined at various tissues one week later.
While a significantly higher frequency of OT-I cells was observed in the spleens
of mice receiving the systemic, relative to the mucosal route of immunization (Fig. 16A),
there was no significant difference in the proportions of these antigen specific CD8 T
cells within the FRT (Fig. 16B). Furthermore, the cytotoxic functionality, in terms of
granzyme B expression, of these CD8 T cells within the FRT was also not significantly
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different between mice receiving the systemic versus intranasal immunization (Fig. 16C),
suggesting that both routes of vaccination are equally efficient in inducing functional
antigen-specific CD8 T cell responses within the female reproductive tract.
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Fig. 16. Mucosal and systemic routes of immunization induce similar antigen
specific immune response at FRT. Mice were adoptively transferred with 1x106 OT-I
cells one day prior to being treated with either intranasal or systemic administration of
OVA or OVA + α-GalCer + CpG-ODN. Percentages of OT-I cells were examined in the
spleen and FRT of treated mice (A, B). Granzyme B expressing CD8 T cells were
examined within the FRT (C). Statistical significance was calculated using the one-way
ANOVA test with multiple comparisons. p>0.05 (ns) p<0.005 (**), p<0.0005 (***).
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Based on the data showing the potency of systemic immunization to induce
antigen-specific cytotoxic CD8 T cell responses in the FRT, I also compared mucosal
and systemic routes of TVAC delivery to treat vaginal HPV tumors Since it is known that
multiple doses of α-GalCer delivered via systemic route of immunization induce NKT cell
anergy, and thereby impede development of adaptive immunity to co-administered
antigens [107], for subcutaneous immunization mice were dosed only once with TVAC
(containing the α-GalCer along with CpG-ODN) on day 5.
Delivery of TVAC by either SC or IN route was equally effective at treating the
HPV vaginal tumors as observed in terms of tumor growth and survival (Fig. 17A).
Analysis of TILs suggested that intranasal immunization was more efficient at inducing
CD8 antigen specific T cells in the tumor, when compared to SC immunization (Fig. 17C,
17D). Despite this difference, overall efficacy in terms of survival advantage was not
statistically different in mice receiving the TVAC by the two different routes.
This data indicates that the therapeutic HPV peptide vaccine containing α-GalCer
and CpG adjuvants (TVAC) is equally effective when delivered in two doses by the
intranasal route or in one dose by the subcutaneous route at eliciting anti-tumor immunity
and efficacy.
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Fig. 17. Single dose of SC TVAC is effective at treating vaginal tumors. Vaginal
tumor bearing mice were immunized on days 5 and 11, intranasally, as previously
described, or only on day 5 via the subcutaneous route and monitored for tumor growth
and survival (A, B). Tumor infiltrating lymphocytes were analyzed on day 18 post-tumor
implantation and are reported as frequency of parent population (C, D). Statistical
significance was calculated using one-way ANOVA with multiple comparisons. p<0.005
(**).
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
Data from this dissertation demonstrates the antitumor efficacy of mucosal
intranasal vaccination regimen comprised of peptides corresponding to immunogenic
sequences in the HPV-16 oncoproteins E6 and E7 and the combination of α-GalCer and
CpG-ODN adjuvants (TVAC) in an established preclinical HPV genital tumor mouse
model. This is particularly significant because sustained tumor regression-free survival
was achieved solely by vaccine-induced cytotoxic effector immunity successfully
overcoming the immunosuppressive tumor microenvironment. Importantly, the
therapeutic vaccine formulation was effective without the need to employ immune
checkpoint therapy that often suffers from systemic toxicities [128, 137]. Despite many
efforts to overcome the toxicities [138, 139], treatment related costs, widespread
availability/accessibility, and ease of administering ICT to patients in resource-limited
areas of the world are the major hurdles. In this regard, the needle-free intranasal
vaccination regimen employing clinically relevant adjuvants to promote immunogenicity
demonstrated to be efficacious in this investigation may be an ideal choice for the
treatment of HPV+ cervical cancer. Our data demonstrates that in the absence of ICT,
intranasally delivered TVAC exerted significant induction of antigen-specific CD8 T cells
resulting in substantial increase in the ratios of effector CD8 T cells to the
immunosuppressive Tregs and MDSCs within the TME.
Additionally, serum levels of liver enzymes AST and ALT that serve as surrogates
for toxicity measurements were comparable between mice with vaginal HPV tumors in
the untreated control group and those treated with the therapeutic HPV peptide vaccine
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containing the combination of α-GalCer and CpG-ODN adjuvants. However, these
measurements of liver toxicity in mice receiving the α4–1BB ICT were significantly above
the normal range (Fig. 7).
We reported earlier that the significant antitumor efficacy afforded by the
therapeutic HPV peptide vaccination employing α-GalCer adjuvant and supplemented
α4-1BB ICT was the induction of a unique subset of Eomesodermin expressing CD4 and
CD8 T cells with high cytotoxic potential (ThEO and TcEO cells, respectively) owing to
their capacity for producing multiple granzymes [140]. Even though TVAC treated mice
did not exhibit induction of this novel T cells subsets, the frequencies of total and antigenspecific CD8 T cells as well as the antitumor efficacy in terms of tumor regression-free
survival were comparable. It is possible that the therapeutic efficacy of TVAC may be
also due to the engagement of other cytotoxic effector mechanism including the
contributions from NK cells and/or NKT cells, a possibility that needs to be evaluated in
future studies. Since the tumor killing functions of the CD8 T cells were not directly
assessed in either of the treatments (α4-1BB supplemented single-adjuvant vaccine and
TVAC), it is difficult to surmise whether enhanced cytotoxic potential of CD8 T cells was
an important feature of efficacy in the TC-1 vaginal tumor model.
The unique therapeutic potential of TVAC is likely due to the ability of the adjuvant
combination, relative to each adjuvant alone, in the vaccine to impart dual licensing of
dendritic cells and promoting induction of stronger CD8 T cell responses. While CpGODN is known to induce dendritic cell (DC) activation through Toll-Like Receptor (TLR)
9 signaling, referred to as classical licensing, α-GalCer engages NKT cells to promote
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strong maturation of DCs, a phenomenon referred to as alternative licensing [26, 141]. It
is suggested that DC receiving the signals from dual licensing can induce strong
recruitment and activation of naïve CD8 T cells through the actions of two independent
sets of chemokines [122, 142, 143]. It is therefore possible that the combination of αGalCer and CpG-ODN adjuvants, relative to each adjuvant alone, and intranasal delivery
enabled promotion of strong antigen-presentation in mucosal DCs, resulting in the
induction and recruitment of high levels of antigen-specific CD8 T cells to the tumor.
While studies in this investigation were limited by less efficient isolation of adequate
numbers of mucosal dendritic cells from the nasal associated lymphoid tissues, it is
known that higher DC activation is directly correlated with enhanced antigen presentation
and thus CD8 response.

Within the tumors of mice treated with TVAC, higher

frequencies of overall CD8 T cell as well as functional subsets of HPV-specific CD8 T
cells expressing granzyme B were observed, and the number of CD8 T cells exceeded
those of the immunosuppressive Tregs and MDSCs together. This data showing
significant induction of functional CD8 T cells in mice treated with TVAC is in line with
reports in the literature for their role in antitumor efficacy, and proved to be the primary
driver of protective immunity in the vaginal TC-1 model, as CD8 depletion completely
abrogated vaccine efficacy (Fig. 4) [144]. Compatibility of different TLR agonists with αGalCer for enhanced DC-mediated activation of CD8 T cells has been described in vitro
using co-cultures of DC and T cells and after subcutaneous delivery in vivo [109, 110,
122, 145-147]. However, my results show for the first time the effectiveness of α-GalCer
in combination with TLR9 agonist for intranasal route of vaccination to promote induction
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of functional antigen-specific CD8 T cell responses in systemic and mucosal tissues, and
more importantly for curative efficacy against HPV genital tumors. These results are in
line with previous data from our group that showed intranasal delivery of vaccines is an
effective strategy to drive significant levels of antigen-specific CD8 T cell responses at
the genital mucosa [117].
Intranasally delivered TVAC was also effective at treating subcutaneously
implanted tumors in the flank supporting its wider utility in cases where the cancer has
spread out of the genital mucosal tissues. Albeit, the efficacy of TVAC was significantly
reduced against larger size tumors, despite the induction of strong CD8 T cell response,
implicating that the larger flank tumors may have significantly accumulated suppressor
cells, as commonly seen in patients [19]. Interestingly, however, depletion of MDSCs
alone was not enough to overcome immune suppression and restore antitumor efficacy
of TVAC (Fig. 14). These results suggest contribution of additional immune suppressive
populations like Tregs in the tumor microenvironment and a combined depletion of both
MDSCs and Tregs at the start of tumor induction could improve antitumor efficacy of the
vaccination regimen. It is therefore, important and informative to determine whether the
frequency and/or density of functional populations of total and antigen specific CD8 T
cells within the tumor are sufficient for inducing tumor regression. In this aspect, recent
investigations of MDSCs have identified subsets with

differing immunosuppressive

potentials, therefore, inclusion of additional markers for characterization of these subsets
and determining functionality of tumor-infiltrating MDSCs would be beneficial to further
understand the effector : suppressor cell populations within the HPV tumors in future
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studies [148]. Because surface markers and gating strategies alone cannot discriminate
some MDSC subsets from monocytes and neutrophils, one method of identifying MDSC
functionality is the inclusion of a marker to detect Arginase [149]. Arginase is an enzyme
produced by immunosuppressive MDSCs which depletes L-Arginine, inhibiting T-cell
function [150]. In addition, in-vitro studies co-culturing purified suppressor MDSCs with
increasing number of effector cells is an alternate option for further investigating the
effector to suppressor cell ratios within the TME. Additionally, analysis for the expression
of immune checkpoint inhibitory receptors/ligands (such as PDL-1/PD-1) within the tumor
microenvironment as well as comparison of the ratios of CD8: MDSC + Treg cells in
relation to tumor size would be instrumental to further refine the intranasal vaccination
strategy described in this investigation.
Another important aspect of the intranasal route of TVAC delivery that included
delivering multiple doses of the vaccine formulation containing the α-GalCer and CpGODN adjuvants to inducing immunity at the FRT is the ability to circumvent NKT cell
anergy, which results from multiple doses of α-GalCer if delivered by systemic
immunization [151, 152]. Even though this investigation did not specifically determine
repeated activation of iNKT cells after each vaccination, previous reports from our lab
have showed the increase of antigen specific T cell immunity resulting from multiple
mucosal doses of α-GalCer as a result of repeated NKT cell stimulation [105, 107]. It
would be useful to also investigate the effect of administering multiple doses of α-GalCer
and CpG-ODN by the intranasal route on different NKT cell subsets. In this regard it is
known that type 2 NKT cells are predominant among the different NKT cells subsets in
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humans and may be an essential cell population for overcoming immune suppression in
tumors [132, 133]. Interestingly, recent literature reports suggest that targeting these
type 2 NKT population through the use of CpG-ODN can shift their immune suppression
phenotype to an inflammatory anti-tumor response [153, 154].
Although NK depletion studies using the anti-PK136 antibody did not significantly
decrease the efficacy of TVAC in the vaginal tumor model (Fig. 10), we cannot conclude
that NK1.1 expressing cells (including NKT cells) are unnecessary for TVAC efficacy. In
fact, if NKT cells, in particular, did not contribute to TVAC efficacy, we would expect TVC
to induce similar anti-tumor results as TVAC since α-GalCer specifically induces antitumor immunity through NKT cell engagement and activation. One explanation as to
why NK1.1 depletion antibody resulted in minimally reduced TVAC efficacy is due to the
NK1.1 negative NKT cell subsets. Studies show that circulating and thymic immature
NKT cells do not express NK1.1, and NKT cells activated in vitro, also downregulate
NK1.1 [155]. Therefore, it is possible that immature NKT cells contributed to the TVAC
efficacy in mice treated with PK136 antibody.
Several groups are currently developing models to further study NK and NKT cells
separately, and understandably it is a difficult task due to the many shared phenotypic
markers and functions.

One group described the development of an NKT specific

monoclonal antibody that could be utilized in future studies for further investigation of
NKT cells vs NK cells in TVAC efficacy [156].
While the majority of results from this investigation established the advantages for
inducing protective immunity of a 2-dose regimen of TVAC delivered by the mucosal
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intranasal route, one dose of TVAC delivered via the subcutaneous systemic (SC) route
also exhibited anti-tumor efficacy against genital HPV tumors (Fig. 17). However, one
caveat to concluding equal potency of systemic vaccination to induce protection against
the vaginal mucosal tumors is that the SC vaccination was administered close to the hind
limbs, and therefore, it is likely that a combination of the lymphatic drainage pattern and
nearby inflammatory tumor environment aided in directing the antigen-specific immune
responses to the FRT [157]. It is therefore, important to test the efficacy of TVAC
delivered at a different SC location such as the back of the neck and analyzing the
draining lymph nodes as well as vaginal tumor infiltrating lymphocytes.
Overall, results from this investigation demonstrated the efficacy TVAC against
established vaginal tumors and smaller size flank tumors via induction of strong total and
antigen-specific cytotoxic effector CD8 T cells. Both the vaccine and the immunization
regimen were however less optimal for treating much advanced bigger size tumors where
additional strategies to overcome immune suppression may have to be explored. Given
this, it is tempting to speculate that mucosal intranasal delivery of TVAC could be an
option to treat pre-cancerous cervical intraepithelial lesions (CIN) that are detected
during a pap smear testing procedure. However, standard practice after a CIN (stage I)
diagnosis is to wait and determine whether the infection and pre-cancerous growth
resolves itself within a few months. If the growth is not naturally resolved, it progresses
to CIN II/III stages and those patients undergo surgery for the removal of the affected
area, which pose quality of life concerns. In this setting it could be advantageous to
implement therapeutic vaccination such as the TVAC developed in this investigation as
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an early treatment option. Unfortunately, there are no currently available preclinical
models for pre-cancerous lesions. In this regard, a recent study described the potential
of a new, infection-based HPV tumor model for HPV head and neck squamous cell
carcinomas which could be promising for use as a vaginal tumor model as well [158].
HPV infections naturally take several years to develop, thereby allowing the tumor
microenvironment

to

initiate

immune-suppression

mechanisms,

otherwise

not

established in orthotopic models such as the one utilized here. Additionally, some critics
argue that inflammation is induced during the tumor implantation process, aiding
whatever therapeutic treatment administered, however, an infection-based model such
as the one described above could circumvent these concerns.

In future studies,

intranasal administration of TVAC in primates would be necessary to ensure proper and
robust Th1 immunity at the FRT prior to promoting this therapeutic approach in clinics.
It would also be interesting to compare with the therapeutic HPV synthetic long peptide
(SLP) vaccine, which has shown some level of efficacy against high-grade vulvar lesions
but was ineffective against invasive cervical cancer in clinical trials[159-161].
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